Best Pharmaceutical Partnership with the NHS 

Best Pharmaceutical Partnership with the NHS 
Best Pharmaceutical Partnership with the NHS 
Read more

How to enter

Entries are now closed

Over the last few years, the NHS has increasingly worked with pharmaceutical companies to deliver improved services to patients. Partnerships between trusts and the pharma industry are varied and represent a range of projects from access and treatment pathways to service and capacity improvements.   

The judges will be looking for innovative projects which demonstrate best practice and deliver benefits which would have been impossible for the NHS to do by itself. They are likely to deal with a specific patient group and could include audit and data analysis; care co-ordination and new pathways for patients. As well as helping the NHS provide better services within financial constraints, they should offer ongoing benefits after any initial set up period. Crucially, they must add value and not just replicate something the NHS could do for itself. 

Eligibility

  • Pharmaceutical companies supplying services in partnership with NHS organisations 
  • Single partnership or joint working projects 
  • Any size of project may apply, and judges will be reviewing impact and efficacy 
  • Project must be ongoing or should have been completed with results relevant to the past two years up until the awards deadline date 

Ambition

  • Outline the depth and breadth of the joint working project and why it was necessary for the NHS organisation to seek such a partnership.   
  • What were the goals of the project and why did joint working bring more to the table than any other solution?  
  • Who was the project serving and how were all stakeholders considered in the brief?  

Outcome

  • What were the measures of success and how were they achieved against the goals laid out at the commencement of the project?  
  • How did the scope of work or goals change throughout the project, and what checks were put in place to ensure these delivered value for money?  
  • Describe key financial outcome metrics as well as clearly demonstrated improvements in patient outcomes, staff ability to treat more patients, improved service delivery or better analysis of patient data.  

Spread

  • If the partnership has proven a success have any of the best practice elements or methodologies been adopted by other departments within the NHS organisation?  
  • What efforts have been made to disseminate success outside of commercial arrangements for the benefit of patients and staff?   
  • Judges will be looking for examples, supported with evidence of take up from other organisations even if neither partner was involved in execution.  

Involvement 

  • How was the introduction of a pharmaceutical provider received by other teams within the organisation, and how were any apprehension or reservations addressed? 
  • Provide demonstrable evidence of comprehensive stakeholder engagement with testimonials and project planning examples.  
  • How was the impact of the partnership on wider departments and organisations handled and how were those teams managed within the scope of the project?  

Value

  • How has the partnership led to material and measurable improvements for patients and staff within the NHS organisation? 
  • What financial benefits have been realised by the partnership, and to what extent has the NHS received value for money against their investment in the project? 
  • Describe and evidence any other value measures and how they were realised. 

To find out more

For entry enquiries, contact James Elliot on james.elliott@wilmingtonplc.com